GlassScriptPhysician profile
Mazen S Daoud
NPI 1316903560
$1,911.27
in general payments reported to CMS, 2019-2025
20 companies · $93.95 in 2025
The $93.95 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $178 · 2021: $293 · 2022: $407 · 2023: $296 · 2024: $324 · 2025: $93.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.06 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.14 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Novartis Pharmaceuticals Corporation | $237.94 | 2019-2024 | |
| Janssen Biotech, INC. | $198.32 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $190.84 | 2021-2024 | |
| Pfizer INC. | $157.71 | 2019-2023 | |
| Lilly USA, LLC | $149.42 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $131.39 | 2021-2025 | Dupixent |
| Ucb, INC. | $77.00 | 2022-2025 | Bimzelx |
| Leo Pharma INC. | $60.79 | 2023-2024 | Adbry |
| Genentech USA, INC. | $48.85 | 2021 | |
| Biofrontera INC. | $47.96 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $43.59 | 2022-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.56 | 2023 | Spevigo |
| Galderma Laboratories, L.P. | $27.48 | 2020-2024 | |
| Dermavant Sciences, INC. | $22.47 | 2024 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $19.55 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $18.70 | 2020 | |
| Verrica Pharmaceuticals INC. | $17.25 | 2023 | Ycanth |
| Sebela Pharmaceuticals INC. | $14.45 | 2023 | Naftin |
| Icad, INC | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.